|
|
Office Locations:
|
1 Main Street, 13th Floor
Cambridge, MA 02142
Phone: 617-231-2400
| |
|
|
|
|
Financial Services
Information Technology
Life Sciences & Healthcare
|
|
|
F-Prime is made up of a portion of Devonshire Investors and the former Fidelity Investments, which was founded in 1946 as a single mutual fund and grew into one of the largest asset management firms in the world, with over $2 trillion in assets under management. The firm also includes sister fund Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai. In healthcare, F-Prime focuses on Biopharmaceuticals, MedTech, and Healthcare IT/Services in a stage-agnostic fashion. In technology, the firm focuses on Enterprise IT and FinTech, with a strong enterprise focus in both.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
COMPANY STAGE | REVENUE |
Venture Capital | |
Seed Stage (includes "pre-seed," or concept stage) | No Revenue |
Early Stage | Minimal Revenue |
Growth Stage (also called Mid-stage) | $2M-$7M |
Expansion Stage (also called Late-stage) | $7M and greater |
Private Equity | |
Lower Middle Market | $10M-$249M |
Middle Market | $250M-$499M |
Upper Middle Market | $500M-$1B |
Large Cap | >$1B |
|
|
|
|
|
Name | |
| |
Title | |
|
Alex Pasteur | |
Ph.D. | |
Partner | |
Anastasiya Sybirna | |
Ph.D. | |
Associate | |
Carl Byers | |
| |
Executive Partner | |
David Jegen | |
| |
Managing Partner | |
Jessica Alston | |
Ph.D. | |
Partner | |
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
12/19/2024
|
TripSuite
|
NY
|
$5,000,000
|
Seed
|
12/11/2024
|
Albert Invent
|
CA
|
$22,500,000
|
Series A
|
11/18/2024
|
Zenflow
|
CA
|
$24,000,000
|
Series C
|
11/12/2024
|
Notabene
|
NY
|
$14,500,000
|
Series B
|
10/22/2024
|
AvenCell Therapeutics
|
MA
|
$112,000,000
|
Series B
|
09/24/2024
|
Centivo
|
NY
|
$75,000,000
|
Venture Debt & Equity
|
08/27/2024
|
Space and Time Labs
|
CA
|
$20,000,000
|
Series A
|
08/15/2024
|
Chaos Labs
|
NY
|
$55,000,000
|
Series A
|
08/15/2024
|
Quantum Circuits Inc
|
CT
|
$60,000,000
|
Series B
|
07/09/2024
|
Canoe Intelligence
|
NY
|
$36,000,000
|
Series C
|
06/27/2024
|
Odaseva
|
CA
|
$54,000,000
|
Series C
|
06/27/2024
|
RareCyte
|
WA
|
$20,000,000
|
Venture
|
06/12/2024
|
Canary Technologies
|
CA
|
$50,000,000
|
Series C
|
06/03/2024
|
Ashby
|
CA
|
$30,000,000
|
|
05/21/2024
|
Expressable
|
TX
|
$26,000,000
|
Series B
|
03/19/2024
|
Engrail Therapeutics
|
CA
|
$157,000,000
|
Series B
|
03/04/2024
|
Nocion Therapeutics
|
MA
|
$62,000,000
|
Series B
|
01/11/2024
|
Dispatch Data
|
FL
|
$8,000,000
|
Seed
|
|
|
|
|
|